Selected research
Industry Research
Acute Myeloid Leukaemia Therapeutics Industry Research Report 2026
Market perspective
The global Acute Myeloid Leukaemia Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Acute Myeloid Leukaemia Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Acute Myeloid Leukaemia Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Acute Myeloid Leukaemia Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Acute Myeloid Leukaemia Therapeutics include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Acute Myeloid Leukaemia Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acute Myeloid Leukaemia Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acute Myeloid Leukaemia Therapeutics Market by Company
Pfizer Inc.
Novartis AG
Celgene Corporation
Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals
Boehringer Ingelheim International GmbH
Johnson & Johnson
Gilead Sciences, Inc.
Amgen Inc.
Takeda Pharmaceutical Company Limited
Sunesis Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Acute Myeloid Leukaemia Therapeutics Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hypomethylating Agents
Others
Acute Myeloid Leukaemia Therapeutics Segment by Application
Specialty Clinics
Hospital
Others
Acute Myeloid Leukaemia Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukaemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukaemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukaemia Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Acute Myeloid Leukaemia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hypomethylating Agents
- Others
Applications
- Specialty Clinics
- Hospital
- Others
Companies covered
- Pfizer Inc.
- Novartis AG
- Celgene Corporation
- Astellas Pharma Inc.
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals
- Boehringer Ingelheim International GmbH
- Johnson & Johnson
- Gilead Sciences, Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Sunesis Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Acute Myeloid Leukaemia Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chemotherapy
- 2.2.3 Targeted Therapy
- 2.2.4 Immunotherapy
- 2.2.5 Hypomethylating Agents
- 2.2.6 Others
- 2.3 Acute Myeloid Leukaemia Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Specialty Clinics
- 2.3.3 Hospital
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Acute Myeloid Leukaemia Therapeutics Breakdown Data by Type
- 3.1 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Type (2027-2032)
4 Acute Myeloid Leukaemia Therapeutics Breakdown Data by Application
- 4.1 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Acute Myeloid Leukaemia Therapeutics Market Perspective (2021-2032)
- 5.2 Global Acute Myeloid Leukaemia Therapeutics Growth Trends by Region
- 5.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Acute Myeloid Leukaemia Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Acute Myeloid Leukaemia Therapeutics Market Dynamics
- 5.3.1 Acute Myeloid Leukaemia Therapeutics Industry Trends
- 5.3.2 Acute Myeloid Leukaemia Therapeutics Market Drivers
- 5.3.3 Acute Myeloid Leukaemia Therapeutics Market Challenges
- 5.3.4 Acute Myeloid Leukaemia Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Acute Myeloid Leukaemia Therapeutics Players by Revenue
- 6.1.1 Global Top Acute Myeloid Leukaemia Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Acute Myeloid Leukaemia Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Acute Myeloid Leukaemia Therapeutics Head Office and Area Served
- 6.4 Global Acute Myeloid Leukaemia Therapeutics Players, Product Type & Application
- 6.5 Global Acute Myeloid Leukaemia Therapeutics Manufacturers Established Date
- 6.6 Global Acute Myeloid Leukaemia Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
- 7.2 North America Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
- 8.2 Europe Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
- 10.2 South America Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer Inc.
- 12.1.1 Pfizer Inc. Company Information
- 12.1.2 Pfizer Inc. Business Overview
- 12.1.3 Pfizer Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.1.5 Pfizer Inc. Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Celgene Corporation
- 12.3.1 Celgene Corporation Company Information
- 12.3.2 Celgene Corporation Business Overview
- 12.3.3 Celgene Corporation Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.3.5 Celgene Corporation Recent Developments
- 12.4 Astellas Pharma Inc.
- 12.4.1 Astellas Pharma Inc. Company Information
- 12.4.2 Astellas Pharma Inc. Business Overview
- 12.4.3 Astellas Pharma Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.4.5 Astellas Pharma Inc. Recent Developments
- 12.5 Daiichi Sankyo Company, Limited
- 12.5.1 Daiichi Sankyo Company, Limited Company Information
- 12.5.2 Daiichi Sankyo Company, Limited Business Overview
- 12.5.3 Daiichi Sankyo Company, Limited Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.5.5 Daiichi Sankyo Company, Limited Recent Developments
- 12.6 Jazz Pharmaceuticals
- 12.6.1 Jazz Pharmaceuticals Company Information
- 12.6.2 Jazz Pharmaceuticals Business Overview
- 12.6.3 Jazz Pharmaceuticals Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.6.5 Jazz Pharmaceuticals Recent Developments
- 12.7 Boehringer Ingelheim International GmbH
- 12.7.1 Boehringer Ingelheim International GmbH Company Information
- 12.7.2 Boehringer Ingelheim International GmbH Business Overview
- 12.7.3 Boehringer Ingelheim International GmbH Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.7.5 Boehringer Ingelheim International GmbH Recent Developments
- 12.8 Johnson & Johnson
- 12.8.1 Johnson & Johnson Company Information
- 12.8.2 Johnson & Johnson Business Overview
- 12.8.3 Johnson & Johnson Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.8.5 Johnson & Johnson Recent Developments
- 12.9 Gilead Sciences, Inc.
- 12.9.1 Gilead Sciences, Inc. Company Information
- 12.9.2 Gilead Sciences, Inc. Business Overview
- 12.9.3 Gilead Sciences, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.9.5 Gilead Sciences, Inc. Recent Developments
- 12.10 Amgen Inc.
- 12.10.1 Amgen Inc. Company Information
- 12.10.2 Amgen Inc. Business Overview
- 12.10.3 Amgen Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.10.5 Amgen Inc. Recent Developments
- 12.11 Takeda Pharmaceutical Company Limited
- 12.11.1 Takeda Pharmaceutical Company Limited Company Information
- 12.11.2 Takeda Pharmaceutical Company Limited Business Overview
- 12.11.3 Takeda Pharmaceutical Company Limited Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.11.5 Takeda Pharmaceutical Company Limited Recent Developments
- 12.12 Sunesis Pharmaceuticals, Inc.
- 12.12.1 Sunesis Pharmaceuticals, Inc. Company Information
- 12.12.2 Sunesis Pharmaceuticals, Inc. Business Overview
- 12.12.3 Sunesis Pharmaceuticals, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments
- 12.13 Agios Pharmaceuticals, Inc.
- 12.13.1 Agios Pharmaceuticals, Inc. Company Information
- 12.13.2 Agios Pharmaceuticals, Inc. Business Overview
- 12.13.3 Agios Pharmaceuticals, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2021-2026)
- 12.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
- 12.13.5 Agios Pharmaceuticals, Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst